Saturday 17 October 2026
Export COR’s income statement to Excel — free account
Cencora, Inc.
COR Healthcare Medical Distribution
Cencora, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $321.3 billion, up 9.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS grew 11.3%, free cash flow grew 3,385.3% and total debt rose 42.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years, revenue growth for ten; insiders bought in the last twelve months.
340.66
0.75
−0.22%
Follow COR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
20.93 | 23.94 | 40.30 | 38.97 |
+8 more quarters Free account |
P/S ratio |
0.16 | 0.19 | 0.20 | 0.19 | |
P/FCF ratio |
13.31 | 38.15 | 17.97 | 18.89 | |
P/Operating CF |
20.59 | 45.65 | (28.46) | 19.33 | |
P/B ratio |
16.87 | 17.05 | 31.30 | 34.67 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.19 | 0.22 | 0.22 | 0.20 | |
EV/EBITDA |
15.46 | 18.58 | 19.22 | 17.28 | |
EV/Operating CF |
13.19 | 31.34 | 16.73 | 16.48 | |
EV/FCF |
15.48 | 44.52 | 19.66 | 19.92 | |
Quick Ratio |
0.48 | 0.48 | 0.47 | 0.51 | |
Current Ratio |
0.93 | 0.95 | 0.92 | 0.90 | |
Net Debt/EBITDA |
6.37 | 7.26 | 6.02 | 11.70 | |
Debt/Assets |
13.99% | 15.17% | 10.11% | 10.00% | |
Debt/Equity |
3.62 | 3.45 | 3.78 | 4.38 | |
Asset Turnover |
4.22 | 4.30 | 4.42 | 4.47 | |
Operating CF/Net income |
3.48 | 0.82 | (4.12) | (9.22) | |
Capex/Depreciation |
(0.81) | (0.63) | (0.29) | (0.95) | |
Interest Coverage |
7.96 | 8.13 | 10.50 | 0.24 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
2.52% | 2.52% | 2.09% | 2.09% | |
Intangible Assets out of Total Assets |
0.27 | 0.28 | 0.22 | 0.23 | |
Share Based Compensation of Revenue |
0.03% | 0.04% | 0.08% | 0.03% | |
Graham Net Nets |
(0.46) | (0.41) | (0.34) | (0.37) | |
Graham Number |
71.42 | 73.75 | 45.11 | 40.33 | |
Earnings Yield |
4.78% | 4.18% | 2.48% | 2.57% | |
Free Cash Flow Yield |
7.51% | 2.62% | 5.56% | 5.29% | |
Revenue per Share |
438.81 | 402.77 | 442.45 | 431.99 | |
Operating CF per Share |
13.74 | 6.88 | (11.87) | 16.17 | |
Capex per Share |
(1.16) | (0.85) | (0.39) | (1.29) | |
Free Cash Flow per Share |
12.58 | 6.03 | (12.26) | 14.88 | |
Cash per Share |
14.58 | 11.19 | 9.03 | 22.48 | |
Shareholders Equity per Share |
16.77 | 18.43 | 10.79 | 9.01 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
16.77 | 18.43 | 10.79 | 9.01 | |
Free Cash Flow |
2,430.06 | 1,173.74 | (2,381.49) | 2,883.61 | |
Working Capital |
(3,861.96) | (2,991.38) | (4,980.57) | (5,581.47) | |
Capital Expenditures |
(224.00) | (164.90) | (76.32) | (249.81) | |
Net Current Asset Value |
(25,231.32) | (24,926.24) | (22,113.67) | (22,603.95) | |
EV/EBIT |
20.90 | 25.57 | 26.75 | 24.30 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
17.97 | 21.91 | 24.45 | 23.04 | |
| Other line items | |||||
Average Receivables |
25,004.92 | 24,304.12 | 25,262.82 | 24,548.56 | |
Average Payables |
52,871.84 | 50,996.19 | 52,987.34 | 52,830.96 | |
Average Inventory |
20,584.10 | 19,487.76 | 22,293.26 | 19,745.66 | |
Average Assets |
78,881.23 | 76,422.99 | 73,707.76 | 71,845.89 | |
Average Common Equity |
2,724.49 | 2,382.38 | 1,228.93 | 1,266.91 |
Columns are period end dates